Metabolic Effects of Replacing Sucrose by Isomaltulose in Subjects With Type 2 Diabetes: A randomized double-blind trial

S. Brunner; I. Holub; S. Theis; A. Gostner; R. Melcher; P. Wolf; U. Amann-Gassner; W. Scheppach; H. Hauner

doi:10.2337/dc11-1485

Metabolic Effects of Replacing Sucrose by Isomaltulose in Subjects With Type 2 Diabetes: A randomized double-blind trial

Diabetes Care ◽

10.2337/dc11-1485 ◽

2012 ◽

Vol 35 (6) ◽

pp. 1249-1251 ◽

Cited By ~ 22

Author(s):

S. Brunner ◽

I. Holub ◽

S. Theis ◽

A. Gostner ◽

R. Melcher ◽

...

Keyword(s):

Type 2 Diabetes ◽

Metabolic Effects ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial

Download Full-text

Faculty Opinions recommendation of Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725388736.793525626 ◽

2016 ◽

Author(s):

Juan-Carlos Kaski ◽

Amelia Carro

Keyword(s):

Heart Failure ◽

Type 2 Diabetes ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial

Download Full-text

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

The Lancet ◽

10.1016/s0140-6736(14)62225-x ◽

2015 ◽

Vol 385 (9982) ◽

pp. 2067-2076 ◽

Cited By ~ 457

Author(s):

Faiez Zannad ◽

Christopher P Cannon ◽

William C Cushman ◽

George L Bakris ◽

Venu Menon ◽

...

Keyword(s):

Heart Failure ◽

Type 2 Diabetes ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial

Download Full-text

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

The Lancet ◽

10.1016/s0140-6736(17)30069-7 ◽

2017 ◽

Vol 389 (10077) ◽

pp. 1399-1409 ◽

Cited By ~ 204

Author(s):

Carel W le Roux ◽

Arne Astrup ◽

Ken Fujioka ◽

Frank Greenway ◽

David C W Lau ◽

...

Keyword(s):

Type 2 Diabetes ◽

Risk Reduction ◽

Weight Management ◽

Diabetes Risk ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial

Download Full-text

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial

BMJ ◽

10.1136/bmj.b4324 ◽

2009 ◽

Vol 339 (nov09 1) ◽

pp. b4324-b4324 ◽

Cited By ~ 20

Author(s):

S. S Lund ◽

L. Tarnow ◽

M. Frandsen ◽

B. B Nielsen ◽

B. V Hansen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Obese Patients ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial ◽

Insulin Secretagogue

Download Full-text

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

The Lancet ◽

10.1016/s0140-6736(19)32131-2 ◽

2019 ◽

Vol 394 (10208) ◽

pp. 1519-1529 ◽

Cited By ~ 44

Author(s):

David R Matthews ◽

Päivi M Paldánius ◽

Pieter Proot ◽

YannTong Chiang ◽

Michael Stumvoll ◽

...

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Double Blind Trial ◽

Newly Diagnosed ◽

Double Blind ◽

Blind Trial ◽

Metformin Monotherapy ◽

Early Combination Therapy

Download Full-text

Efficacy and safety of exenatide as add‐on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double‐blind trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14225 ◽

2020 ◽

Author(s):

Michael Joubert ◽

Victoria Opigez ◽

Barbora Pavlikova ◽

Laure Peyro Saint Paul ◽

Nathalie Jeandidier ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Regimen ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Blind Trial

Download Full-text

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2017.10.018 ◽

2018 ◽

Vol 138 ◽

pp. 253-261 ◽

Cited By ~ 8

Author(s):

Philip Home ◽

R. Ravi Shankar ◽

Ira Gantz ◽

Carol Iredale ◽

Edward A. O'Neill ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Blind Trial ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12620 ◽

2016 ◽

Vol 18 (7) ◽

pp. 711-715 ◽

Cited By ~ 9

Author(s):

A. O. Stirban ◽

M. Andjelkovic ◽

T. Heise ◽

L. Nosek ◽

A. Fischer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Sensitivity ◽

Glucose Control ◽

Peroxisome Proliferator ◽

Double Blind Trial ◽

Lipid Levels ◽

Double Blind ◽

Peroxisome Proliferator Activated Receptor ◽

Blind Trial

Download Full-text

Addition of Mitiglinide to Pioglitazone Monotherapy Improves Overall Glycemic Control in Japanese Patients with Type 2 Diabetes: A Randomized Double Blind Trial

Endocrine Journal ◽

10.1507/endocrj.k09e-022 ◽

2009 ◽

Vol 56 (5) ◽

pp. 657-664 ◽

Cited By ~ 8

Author(s):

Kohei KAKU ◽

Shun-ichi TANAKA ◽

Hideki ORIGASA ◽

Masatoshi KIKUCHI ◽

Yasuo AKANUMA

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Japanese Patients ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial

Download Full-text

Review for "Effects of DPP ‐4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8‐week randomized controlled double‐blind trial"

10.1111/dom.14107/v2/review2 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Double Blind Trial ◽

Overweight Patient ◽

Double Blind ◽

Blind Trial ◽

Randomized Controlled

Download Full-text